Following publication of the original article [1], we were notified that the control group in the left panel of Figure 1c was incorrect, the labelling of the control group in Figure 1e was inconsistent.
Casticin inhibits the proliferation and viability of NPC cells in vitro and in vivo. a The chemical structure of casticin. b NP69 and S18 cells were treated with a gradient of casticin concentrations (0, 2, 4, 8, 16 μM) for 24, 48 or 72 h. Cell viability was assessed using the CCK-8 assay. The data are presented as the mean ± SEM, *p< 0.05 versus 0 μM; #p < 0.05 versus 2 μM; &p < 0.05 versus 4 μM; ‡p < 0.05 versus 8 μM. c Casticin inhibits migration of S18 cells in the wound healing assay. White dashed lines indicate the wound edge. The residual gap between the migrating cells from the opposite edges of the wound is represented by a percentage of the initial scratch area. Corresponding graph shows the mean width of the injury lines of three independent experiments (right). All data are presented as the mean ±standard deviation. **p < 0.01 versus DMSO. d Casticin inhibits migration of S18 cells in the Transwell assay. Corresponding graphs in the panel on the right show the mean numbers of cells per high-power field (HPF) from five independent areas. All data are presented as the mean ± standard deviation. *p< 0.05 versus 0 μM, **p < 0.01 versus 2 μM, and ***p< 0.001 versus 4 μM. e, f Colony formation of S18 cells post-treatment with casticin. Cells were exposed to 0, 1, 2, and 4 μM casticin for 12 h or were exposed to a fixed level of 1 μM casticin for different time periods (0, 6, 12, and 24 h) and were then allowed to form colonies for approximately 10 days. Corresponding graphs show the mean number of colonies in different groups for three independent experiments (right). All data are presented as the mean ± standard deviation. Right panel of e *p< 0.05 versus 0 μM, **p< 0.01 versus 1 μM, and ***p< 0.001 versus 2 μM. Right panel of f *p< 0.05 versus 0 h, **p< 0.01 versus 6 h, and ***p< 0.001 versus 12 h; g Casticin (10% DMSO +90% physiological saline, 40 mg/kg) was injected into nude mice every day for 12 days starting 6 days after inoculation with 5 million S18 cells. h Tumour volume was periodically measured for each mouse, and the growth curve was plotted. i Tumours were excised from the animals and weighed. *p < 0.05 versus NS
×
Anzeige
Also, the legend for Figure 2f needs to read: “Levels of expression of apoptosis related proteins BCL2 and BAX in S18 cells with a gradient of casticin concentrations (0, 1, 2, 4 µM), and C666-1 with a gradient of casticn concentrations (0, 2, 4 or 8 µM) analyzed by Western blotting.”
These changes don’t affect any of the conclusions. The authors apologise for any inconvenience.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.
Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.
Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.
Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
